Search Results

You are looking at 1 - 10 of 173 items for :

  • "cetuximab" x
Clear All
Full access

Matthew G. Fury, Eric Sherman, Donna Lisa, Neeraj Agarwal, Kenneth Algazy, Bruce Brockstein, Corey Langer, Dean Lim, Ranee Mehra, Sandeep K. Rajan, Susan Korte, Brynna Lipson, Furhan Yunus, Tawee Tanvetyanon, Stephanie Smith-Marrone, Kenneth Ng, Han Xiao, Sofia Haque and David G. Pfister

The epidermal growth factor receptor (EGFR) is expressed on virtually all head and neck squamous cell cancer (HNSCC) tumors, and high levels of expression have been associated with unfavorable clinical prognosis. 1 , 2 Cetuximab is a chimeric IgG

Full access

Raymond Elsoueidi, Jessica Craig, Hesham Mourad and Elie M. Richa

dysfunction Discuss what is known regarding the safety and efficacy of FOLFOX in the treatment of patients with mCRC and severe liver dysfunction Evaluate available data regarding the safety of cetuximab monotherapy for the treatment of mCRC in patients

Full access

Matthew G. Fury and David G. Pfister

agents in the management of R/M HNSCC Analyze the use of cetuximab in the management of R/M HNSCC General Considerations and Prognostic Factors For patients with recurrent and/or metastatic head and neck squamous cell cancer (R/M HNSCC) who are considered

Full access

Bruce Brockstein, Mario Lacouture and Mark Agulnik

Edited by Kerrin G. Robinson

. Cancer Res 1993 ; 53 : 3579 – 3584 . 24. Imai K Takaoka A . Comparing antibody and small-molecule therapies for cancer . Nat Rev Cancer 2006 ; 6 : 714 – 727 . 25. Kawaguchi Y Kono K Mimura K . Cetuximab induce antibody

Full access

Joseph Rosales and Lucille A. Leong

. 18 Tournigand C Andre T Achille E . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study . J Clin Oncol 2004 ; 22 : 229 – 237 . 19 Cunningham D Humblet Y Siena S . Cetuximab

Full access

David M. Brizel, William Lydiatt and A. Dimitrios Colevas

, elimination of cisplatin-based concurrent systemic therapy, use of alternative systemic agents such as cetuximab, or an increased reliance on primary surgical therapy instead of (chemo)radiation have all been proposed. The crux of the debate is whether

Full access

Lyndsay J. Willmott, Daniele A. Sumner and Bradley J. Monk

adverse events being gastrointestinal, fatigue, and rash. The authors concluded that erlotinib was inactive as monotherapy in patients with recurrent squamous cell carcinoma of the uterine cervix. 30 Cetuximab is another drug targeting EGFR that has been

Full access

Barbara Burtness, Milan Anadkat, Surendra Basti, Miranda Hughes, Mario E. Lacouture, Joan S. McClure, Patricia L. Myskowski, Jennifer Paul, Clifford S. Perlis, Leonard Saltz and Sharon Spencer

. 4 Saltz L Rubin M Hochster H . Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [Abstract] . Proc Am Soc Clin Oncol 2001 ; 20

Full access

Al B. Benson III, J. Pablo Arnoletti, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Paul F. Engstrom, Peter C. Enzinger, James W. Fleshman Jr., Charles S. Fuchs, Jean L. Grem, James A. Knol, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr., Constantinos T. Sofocleous, Alan P. Venook and Christopher Willett

bevacizumab, cetuximab, panitumumab, or irinotecan in adjuvant therapy for nonmetastatic disease outside the setting of a clinical trial. Adenocarcinomas of the small bowel or appendix, for which no NCCN Guidelines exist, may be treated with systemic

Full access

Zi-Xian Wang, Hao-Xiang Wu, Ming-Ming He, Ying-Nan Wang, Hui-Yan Luo, Pei-Rong Ding, Dan Xie, Gong Chen, Yu-Hong Li, Feng Wang and Rui-Hua Xu

efficacy of chemotherapy + cetuximab (Cet) or panitumumab (Pani) versus chemotherapy ± bevacizumab (Bev) reported significant improvement in overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) with chemotherapy + Cet